Long-term #PEACE1 data at #ESMO26 reinforce the survival benefit of treatment intensification in de novo mHSPC #KarimFizazi @OncoAlert
ADT + docetaxel + abiraterone vs doublet:Median OS: 6.2 vs 4.4 years
8-year OS: 40% vs 27%
89 浏览 · 4 赞 · 4 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com